Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist widely explored in laboratory and experimental research settings related to metabolic regulation, glucose-homeostasis pathways, appetite-related signaling, and adipose-related research models
doi: 10.1038/s41538-017-0005-1, 209
They have been highly effective in helping patients with T2D meet glycemic targets, 1 achieve substantial weight loss, 2 and improve cardiometabolic and kidney outcomes in high-risk subgroups
The closest human evidence in Dihexa's drug class is a different molecule
All statistical analyses were performed using SPSS version 10 (SPSS, Inc., Chicago, IL, USA)
1 2025 Cigna Healthcare Book of Business data 2 Cigna Healthcare 2025 National Book of Business study of 2024 claims of medical customers who have Cigna Healthcare integrated medical, pharmacy and Cigna Total Behavioral Health benefits
US$ 28.20
US$ 27.78
US$ 21.79
US$ 25.46
US$ 27.49
